Want to see PRLD full AI Analyst Report?
Top Page
Prelude Therapeutics
(NASDAQ:PRLD)
Select Model
Select Model
Rating:51Neutral
Price Target:
$5.00
▲(28.53% Upside)
Action:Reiterated
Date:08/11/26
The score is held back primarily by continued large losses and still-negative free cash flow despite improving burn. Technicals are moderately positive with price above major moving averages, and corporate events (financing/runway extension and pipeline progress) are supportive, but valuation remains constrained by unprofitability and lack of a dividend.
Positive Factors
Revenue Growth & Margin
Meaningful multi-year revenue scaling alongside an extremely high gross margin signals that reported revenues (largely collaboration/licensing) carry favorable economics. Durable high margins improve the capital efficiency of incremental partnership revenue and support funding runway for R&D programs.
Negative Factors
Persistent Negative Cash Flow
Despite improvement versus prior years, sustained negative operating and free cash flow indicate the business is not yet self-funding. Continued burn makes the company dependent on external capital to advance programs, raising dilution and execution risk if financings become constrained or costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Margin
Meaningful multi-year revenue scaling alongside an extremely high gross margin signals that reported revenues (largely collaboration/licensing) carry favorable economics. Durable high margins improve the capital efficiency of incremental partnership revenue and support funding runway for R&D programs.
Read all positive factors
Prelude Therapeutics (PRLD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$524.65M
Dividend YieldN/A
Average Volume (3M)256.05K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue Growth220.34%
EPS Growth55.73%
CountryUS
Employees79
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding79,803,480
10 Day Avg. Volume194,393
30 Day Avg. Volume256,051
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.25
Price to Sales (P/S)18.38
P/FCF Ratio-3.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside105.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Prelude Therapeutics Business Overview & Revenue Model
Company Description
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently underg...
How the Company Makes Money
Prelude Therapeutics does not have recurring revenue from marketed products as a clinical-stage company. Its reported revenue, when present, is primarily generated through collaborations and licensing arrangements with other biopharmaceutical comp...
Prelude Therapeutics Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
60
Neutral
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.42M | 12.14M | 7.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 22.03M | 10.43M | 7.00M | 0.00 | 0.00 | 0.00 |
| EBITDA | -58.90M | -97.79M | -125.40M | -120.66M | -114.11M | -110.78M |
| Net Income | -60.49M | -99.50M | -127.17M | -121.83M | -115.44M | -111.69M |
Balance Sheet | ||||||
| Total Assets | 189.36M | 141.31M | 175.51M | 277.67M | 220.50M | 305.10M |
| Cash, Cash Equivalents and Short-Term Investments | 151.76M | 103.21M | 133.61M | 232.94M | 201.73M | 291.23M |
| Total Debt | 17.65M | 17.79M | 18.02M | 16.89M | 1.83M | 1.74M |
| Total Liabilities | 55.63M | 72.68M | 44.06M | 40.58M | 25.06M | 19.20M |
| Stockholders Equity | 133.73M | 68.64M | 131.46M | 237.09M | 195.44M | 285.90M |
Cash Flow | ||||||
| Free Cash Flow | -33.26M | -56.37M | -103.65M | -110.58M | -86.75M | -85.85M |
| Operating Cash Flow | -33.26M | -56.30M | -102.89M | -107.06M | -83.73M | -83.53M |
| Investing Cash Flow | -77.25M | 53.46M | 90.19M | -34.65M | 81.69M | -263.80M |
| Financing Cash Flow | 110.44M | 24.82M | -120.00K | 136.40M | 815.00K | 164.90M |
Prelude Therapeutics Technical Analysis
Positive
3.89
Price Trends
4.52
Positive
4.38
Positive
3.30
Positive
Market Momentum
0.27
Negative
63.72
Neutral
76.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRLD, the sentiment is Positive. The current price of 3.89 is below the 20-day moving average (MA) of 4.62, below the 50-day MA of 4.52, and above the 200-day MA of 3.30, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 63.72 is Neutral, neither overbought nor oversold. The STOCH value of 76.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRLD.
Prelude Therapeutics Risk Analysis
Prelude Therapeutics disclosed 77 risk factors in its most recent earnings report. Prelude Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prelude Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
PRLD
Prelude Therapeutics
5.55
4.61
490.43%
PMVP
PMV Pharmaceuticals
1.26
-0.30
-19.23%
GANX
Gain Therapeutics
2.12
0.35
19.77%
IMMX
Immix Biopharma
10.97
8.67
376.96%
Prelude Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Prelude Therapeutics Shareholders Back Leadership and Governance
Positive
Jun 10, 2026
On June 9, 2026, Prelude Therapeutics held its 2026 Annual Meeting of Stockholders, where shareholders re-elected Class III directors Krishna Vaddi, Paul Scherer, and Katina Dorton to three-year terms expiring at the 2029 annual meeting. Investors...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Prelude Therapeutics Launches Phase 1 Trial and Extends Runway
Positive
May 12, 2026
Prelude Therapeutics reported first-quarter 2026 results on May 12, 2026, highlighting the start of a Phase 1 trial for PRT12396, its mutant-selective JAK2V617F inhibitor for polycythemia vera and myelofibrosis, following U.S. regulatory clearance...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.